[Significance of changed levels of TRACP-5b, PINP and vitamin D3 before and after the treatment of myeloma disease].
作者信息
Ma R J, Zhu Z M, Yuan X L, Jiang L, Yang S W, Yang J, Wang Z, Lei P C, Sun K, Guo J M, Zhang L, Zhang Y
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2018 Aug 14;39(8):685-687. doi: 10.3760/cma.j.issn.0253-2727.2018.08.016.
Abstract
摘要
相似文献
1
[Significance of changed levels of TRACP-5b, PINP and vitamin D3 before and after the treatment of myeloma disease].[骨髓瘤疾病治疗前后血清抗酒石酸酸性磷酸酶5b、I型前胶原氨基端前肽及维生素D3水平变化的意义]
Zhonghua Xue Ye Xue Za Zhi. 2018 Aug 14;39(8):685-687. doi: 10.3760/cma.j.issn.0253-2727.2018.08.016.
2
[The influence and clinical significance of proteasome inhibitor on serum bone metabolite markers in patients with myeloma bone disease].蛋白酶体抑制剂对骨髓瘤骨病患者血清骨代谢标志物的影响及临床意义
Zhonghua Yi Xue Za Zhi. 2020 Jul 14;100(26):2032-2035. doi: 10.3760/cma.j.cn112137-20200328-00988.
3
The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.抗酒石酸酸性磷酸酶5b（TRACP-5b）在监测骨质疏松症抗吸收治疗中的临床应用。
Osteoporos Int. 2022 Jun;33(6):1357-1363. doi: 10.1007/s00198-022-06311-3. Epub 2022 Jan 31.
4
[Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].血清骨代谢标志物在骨髓瘤骨病诊断及监测中的临床意义
Zhonghua Yi Xue Za Zhi. 2015 Nov 10;95(42):3436-9.
5
Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.血清抗酒石酸酸性磷酸酶5b在监测氯膦酸盐双膦酸盐治疗中的应用：与I型胶原尿N端肽及血清I型前胶原氨基端前肽的比较
Osteoporos Int. 2005 Sep;16(9):1109-16. doi: 10.1007/s00198-004-1819-7. Epub 2004 Dec 17.
6
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.抗酒石酸酸性磷酸酶同工型5b：一种用于监测多发性骨髓瘤骨病的新型血清标志物。
Int J Cancer. 2003 Sep 1;106(3):455-7. doi: 10.1002/ijc.11247.
7
Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.地舒单抗停药后 RANKL 和 TRAcP 5b 的变化表明 RANKL 介导致破骨细胞形成导致骨吸收增加。
Osteoporos Int. 2023 Mar;34(3):599-605. doi: 10.1007/s00198-022-06651-0. Epub 2022 Dec 22.
8
Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.血清抗酒石酸酸性磷酸酶5b是监测阿仑膦酸盐治疗的有用标志物：与其他骨转换标志物的比较。
J Bone Miner Res. 2005 Oct;20(10):1804-12. doi: 10.1359/JBMR.050403.
9
TRACP 5b and CTX as osteological markers of delayed fracture healing.TRACP 5b 和 CTX 作为骨折愈合延迟的骨骼标志物。
Injury. 2011 Aug;42(8):758-64. doi: 10.1016/j.injury.2010.11.017. Epub 2010 Dec 17.
10
[Correlation of cytogenetic changes with VEGF and TRacp-5b levels among 60 elderly patients with multiple myeloma].60例老年多发性骨髓瘤患者细胞遗传学改变与VEGF及TRacp-5b水平的相关性
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2016 Oct;33(5):602-5. doi: 10.3760/cma.j.issn.1003-9406.2016.05.004.
本文引用的文献
1
Biology and treatment of myeloma related bone disease.骨髓瘤相关骨病的生物学和治疗。
Metabolism. 2018 Mar;80:80-90. doi: 10.1016/j.metabol.2017.11.012. Epub 2017 Nov 23.
2
New agents in the Treatment of Myeloma Bone Disease.新型骨髓瘤骨病治疗药物。
Calcif Tissue Int. 2018 Feb;102(2):196-209. doi: 10.1007/s00223-017-0351-7. Epub 2017 Nov 2.
3
Myeloma bone disease: pathogenesis and treatment.骨髓瘤骨病：发病机制与治疗
Clin Adv Hematol Oncol. 2017 Apr;15(4):285-295.
4
Emerging treatment approaches for myeloma-related bone disease.骨髓瘤相关骨病的新兴治疗方法。
Expert Rev Hematol. 2017 Mar;10(3):217-228. doi: 10.1080/17474086.2017.1283213. Epub 2017 Jan 29.
5
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease.骨髓瘤细胞的接触会在骨骼前体细胞中诱导出一种特征性的转录组特征——对骨髓瘤骨病的影响。
Bone. 2016 Dec;93:155-166. doi: 10.1016/j.bone.2016.08.006. Epub 2016 Aug 9.
6
[Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers].[多发性骨髓瘤骨病的临床特征及骨代谢标志物监测的临床意义]
Zhonghua Yi Xue Za Zhi. 2016 May 17;96(18):1424-9. doi: 10.3760/cma.j.issn.0376-2491.2016.18.008.
7
[Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].血清骨代谢标志物在骨髓瘤骨病诊断及监测中的临床意义
Zhonghua Yi Xue Za Zhi. 2015 Nov 10;95(42):3436-9.
8
[Mechanisms of osteogenic inhibition in myeloma bone disease and its targeted therapy].[骨髓瘤骨病中成骨抑制的机制及其靶向治疗]
Zhonghua Xue Ye Xue Za Zhi. 2013 Nov;34(11):984-7. doi: 10.3760/cma.j.issn.0253-2727.2013.11.018.
9
The clinical utility of bone marker measurements in osteoporosis.骨标志物测量在骨质疏松症中的临床应用。
J Transl Med. 2013 Aug 29;11:201. doi: 10.1186/1479-5876-11-201.
10
[Myeloma bone disease: pathogenetic mechanisms and targeted therapy].[骨髓瘤骨病：发病机制与靶向治疗]
Zhonghua Xue Ye Xue Za Zhi. 2012 Mar;33(3):247-9.
Zotero 插件